Table 1.

Nano-formulated cancer medicines with granted regulatory approval.

Adapted from de Lazaro and Mooney and Kemp and Kwon and Ventola [130–132]

Product name	Composition	Indications	First approval
SMANCS	Polymer conjugate neocarzinostatin	Liver and renal cancer	Japan (1993)
Doxil/Caelyx	PEGylated liposomal doxorubicin	Myeloma, Kaposi’s sarcoma, ovarian and metastatic breast cancer (Caelyx)	US (1995) Europe (1996)
DaunoXome	Liposomal daunorubicin	Kaposi’s sarcoma	US (1996)
DepoCyt	Liposomal cytarabine	Lymphoma, Leukemia	US (1999)
Myocet	Liposomal doxorubicin	Metastatic breast cancer	Europe/Canada (2000)
Abraxane	Albumin-bound paclitaxel	Non-small-cell lung, metastatic breast and pancreatic cancer	US (2005) Europe (2008)
Lipusu	Liposomal paclitaxel	Breast and non-small-cell lung cancer, metastatic gastric cancer	China (2006)
Nanoxel	Paclitaxel micellar	Solid tumors	India (2006)
Oncaspar	L-asparaginase conjugate	Acute lymphoblastic leukemia	US (2006)
Genexol-PM	Paclitaxel micellar	Breast, non-small-cell lung, ovarian, and gastric cancer	South Korea (2007)
Mepact	Liposomal mifamurtide	Osteogenic sarcoma	Europe (2009)
NanoTherm	Iron oxide NPs	Brain tumor (recurrent glioblastoma)	Europe (2011)
Marqibo	Liposomal vincristine sulfate	Philadelphia chromosome-negative acute lymphoblastic leukaemia, non-small-cell lung cancer	US (2012)
PICN	Polymer/lipid NPs paclitaxel	Metastatic breast cancer	India (2014)
ONIVYDE (MM-398)	Liposomal irinotecan	Advanced (metastatic) pancreatic cancer	US (2015)
DHP107	Paclitaxel lipid NPs (oral administration)	Gastric cancer	South Korea (2016)
Vyxeos	Liposomal daunorubicin and cytarabine	High-risk acute myeloid leukemia	US (2017) Europe (2018)
Apealea	Paclitaxel micellar	Ovarian, peritoneal, and fallopian tube cancer	Europe (2018)
Hensify	Hafnium oxide NPs	Locally-advanced soft tissue sarcoma	Europe (2019)